29
Views
0
CrossRef citations to date
0
Altmetric
Review

Fixed combination therapies in COPD – effect on quality of life

, &
Pages 551-557 | Published online: 20 Oct 2022

References

  • BalterMSLa ForgeJLowDE2003Canadian guidelines for the management of acute exacerbations of chronic bronchitisCan Respir J10Suppl B3B32B
  • BoschettoPQuintavalleSMiottoD2006Chronic obstructive pulmonary disease (COPD) and occupational exposuresJ Occup Med Toxicol11116756686
  • CalverleyPMAndersonJACelliB2007Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med3567758917314337
  • CalverleyPMBoonsawatWCsekeZ2003bMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J229129
  • CalverleyPPauwelsRVestboJ2003aCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet36144956
  • CalverleyPWalkerP2003Chronic obstructive pulmonary diseaseLancet36210536114522537
  • CelliBRCoteCGMarinJM2004The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med35010051214999112
  • CelliBRMacNeeW2004Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J239324615219010
  • FabbriLCaramoriGBegheB1998Chronic obstructive pulmonary disease international guidelinesCurr Opin Pulm Med476849612669
  • FletcherCPetoR1977The natural history of chronic airflow obstructionBMJ116458871704
  • Groneberg-KloftBKrausTvan MarkA2006Analysing the causes of chronic cough: Relation to diesel exhaust, ozone, nitrogen oxides, sulphur oxides and other environmental factorsJ Occup Med Toxicol1616722555
  • HajiroTNishimuraKTsukinoM1998Comparison of discriminative properties among disease-specific questionnaires for measuring health related quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med157785909517591
  • HananiaNADarkenPHorstmanD2003The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest1248344312970006
  • Hansen-FlaschenJH2003Update in pulmonary medicineAnn Intern Med1383192512585830
  • JonesPWQuirkFHBaveystockCMLittlejohnsP1992A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory QuestionnaireAm Rev Respir Dis145132171595997
  • KetelaarsCAJSchlosserMAGMostertR1996Determinants of health-related quality of life in patients with chronic obstructive pulmonary diseaseThorax5139438658367
  • MahlerDAWirePHorstmanD2002Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16610849112379552
  • McSweenyAJGrantIHeatonRK1982Life quality of patients with chronic obstructive pulmonary diseaseArch Intern Med14247387065785
  • MurrayCJLopezAD1997aAlternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyLancet3491498504
  • MurrayCJLLopezAD1997bGlobal mortality, disability, and the contribution of risk factors: Global Burden of Disease StudyLancet349143642
  • MurrayCJLLopezAD1997cMortality by cause for eight regions of the world: Global Burden of Disease StudyLancet349126976
  • MurrayCJLLopezADMathersCDSteinC2001The Global Burden of Disease 2000 Project: global programme on evidence for health policy discussionGenevaWHO, paper number 36.
  • NanniniLCatesCJLassersonTJPooleP2004Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary diseaseCochrane Database Syst RevCD00379415266502
  • National Heart LaBI2002NHLBI morbidity and mortality chartbookBethesdaUS Department of Health and Human Services, Public Health Service
  • PauwelsRABuistASCalverleyPM2001Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Respir Crit Care Med16312567611316667
  • PetoRSpeizerFECochraneAL1983The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observationAm Rev Respir Dis1284915006614643
  • RennardSDecramerMCalverleyPM2002Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International SurveyEur Respir J2079980512412667
  • SiafakasNMVermeirePPrideNB1995Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task ForceEur Respir J813984207489808
  • SocietyAT1987Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986Am Rev Respir Dis136225443605835
  • SorianoJBMaierWCEggerP2000Recent trends in physician diagnosed COPD in women and men in the UKThorax557899410950900
  • SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
  • WelteTGronebergDA2006Asthma and COPDExp Toxicol Pathol57S23540
  • WoutersEFPostmaDSFokkensB2005Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax60480715923248

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.